Sign in Subscribe
Cancer

MRI-Ultrasound Fusion Biopsy Shows Promise in Detecting Clinically Significant Prostate Cancer

Strategic Insights

— 1 min read

Researchers at Yale University School of Medicine have investigated the diagnostic outcomes of MRI-ultrasound fusion targeted biopsy in detecting clinically significant prostate cancer. The study aimed to evaluate the effectiveness of using microUS technology and conventional ultrasound in detecting cancers using targeted biopsy. The researchers analyzed a matched sample of 899 patients who underwent biopsy between January 2017 and January 2023.

Key Takeaways:

  • The study found that the overall incidence of clinically significant prostate cancer (csPCa) was similar between MRI-microUS and MRI-conventional US fusion biopsy groups (53.6% vs. 55.3%, P 0.05).
  • In patients undergoing MRI-microUS fusion biopsy, the detection of any cancer in the seminal vesicles was greater than in the transition zone (69.2% vs. 57.1%, P 2 detection was similar between the two groups (44.9% vs. 40.5%, P = 0.06).
  • MicroUS-guided biopsy and conventional US-guided biopsy had similar rates of overall csPCa detection.
  • Targeted biopsy using MRI-microUS fusion yielded lower overall and csPCa detection compared with MRI-conventional US fusion biopsy.
  • Age, race, biopsy status, PSA density, and PI-RADS score were significantly associated with the detection of clinically significant prostate cancer.

Statistics:

  • A total of 899 patients were included in the study.
  • The study found that 53.6% of patients in the MRI-microUS group had clinically significant prostate cancer, compared to 55.3% in the MRI-conventional US fusion biopsy group.
  • The detection of any cancer in the seminal vesicles was 69.2% in the MRI-microUS group, compared to 57.1% in the transition zone using MRI-conventional US fusion biopsy.
  • The rates of clinically significant prostate cancer detection were similar between microUS-guided biopsy and conventional US-guided biopsy (53.6% vs. 55.3%).
  • The study found that the detection of clinically significant prostate cancer using targeted biopsy with MRI-microUS fusion was lower compared to MRI-conventional US fusion biopsy (53.6% vs. 55.3%).

Sources:

  • "Diagnostic Performance of High-resolution Micro-ultrasound and Conventional Ultrasound In Fusion Biopsy for Clinically Significant Prostate Cancer Detection." Urologic Oncology: Seminars and Original Investigations, 2025;43(6).
  • NewsRx. Researchers from Yale University School of Medicine Report New Studies and Findings in the Area of Cancer Detection (Diagnostic Performance of High-resolution Micro-ultrasound and Conventional Ultrasound In Fusion Biopsy for Clinically ...). Cancer Weekly. July 29, 2025; p 809.

Read more